| Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer JM Mehnert, A Panda, H Zhong, K Hirshfield, S Damare, K Lane, L Sokol, ... The Journal of clinical investigation 126 (6), 2334-2340, 2016 | 376 | 2016 |
| Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma CC Smith, KE Beckermann, DS Bortone, AA De Cubas, LM Bixby, SJ Lee, ... The Journal of clinical investigation 128 (11), 4804-4820, 2019 | 256 | 2019 |
| Immune activation and benefit from avelumab in EBV-positive gastric cancer A Panda, JM Mehnert, KM Hirshfield, G Riedlinger, S Damare, ... JNCI: Journal of the National Cancer Institute 110 (3), 316-320, 2018 | 194 | 2018 |
| Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma A Panda, AA de Cubas, M Stein, G Riedlinger, J Kra, T Mayer, CC Smith, ... JCI insight 3 (16), 2018 | 150 | 2018 |
| Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors A Panda, A Betigeri, K Subramanian, JS Ross, DC Pavlick, S Ali, ... JCO Precision Oncology 1, 1-13, 2017 | 75 | 2017 |
| DNA hypomethylation promotes transposable element expression and activation of immune signaling in renal cell cancer AA de Cubas, W Dunker, A Zaninovich, RA Hongo, A Bhatia, A Panda, ... JCI Insight 5 (11), 2020 | 54 | 2020 |
| Widespread alternative exon usage in clinically distinct subtypes of Invasive Ductal Carcinoma SS Bjørklund, A Panda, S Kumar, M Seiler, D Robinson, J Gheeya, M Yao, ... Scientific Reports 7 (1), 5568, 2017 | 47 | 2017 |
| Genomic and immunologic correlates of LAG-3 expression in cancer A Panda, JA Rosenfeld, EA Singer, G Bhanot, S Ganesan OncoImmunology 9 (1), 1756116, 2020 | 28 | 2020 |
| Tissue-and development-stage–specific mRNA and heterogeneous CNV signatures of human ribosomal proteins in normal and cancer samples A Panda, A Yadav, H Yeerna, A Singh, M Biehl, M Lux, A Schulz, T Klecha, ... Nucleic acids research 48 (13), 7079-7098, 2020 | 22 | 2020 |
| The modular adaptive ribosome A Yadav, A Radhakrishnan, A Panda, A Singh, H Sinha, G Bhanot PloS one 11 (11), e0166021, 2016 | 15 | 2016 |
| SMAD4 is critical in suppression of BRAF-V600E serrated tumorigenesis K Tong, OA Kothari, KS Haro, A Panda, MM Bandari, JN Carrick, JJ Hur, ... Oncogene 40 (41), 6034-6048, 2021 | 14 | 2021 |
| Genomic and immunologic correlates of indoleamine 2, 3-dioxygenase pathway expression in cancer A Panda, S Ganesan Frontiers in Genetics 12, 706435, 2021 | 11 | 2021 |
| 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one: National Harbor, MD, USA. 9-13 November 2016 A Lundqvist, V van Hoef, X Zhang, E Wennerberg, J Lorent, K Witt, ... Journal for immunotherapy of cancer 4, 1-106, 2016 | 10 | 2016 |
| Barrett’s Epithelium to Esophageal Adenocarcinoma: Is There a “Point of No Return”? A Panda, M ryung Shin, C Cheng, M Bajpai Frontiers in Genetics 12, 2021 | 7 | 2021 |
| Recurring Translocations in Barrett’s Esophageal Adenocarcinoma M Bajpai, A Panda, K Birudaraju, J Van Gurp, A Chak, KM Das, P Javidian, ... Frontiers in Genetics 12, 813, 2021 | 3 | 2021 |
| Gene Expression in Barrett’s Esophagus Cell Lines Resemble Esophageal Squamous Cell Carcinoma Instead of Esophageal Adenocarcinoma A Panda, G Bhanot, S Ganesan, M Bajpai Cancers 13 (23), 5971, 2021 | 3 | 2021 |
| Expression of endogenous retroviruses and response to immune checkpoint therapy in renal cell cancer. A Panda, A De Cubas, K Beckermann, G Riedlinger, MN Stein, TM Mayer, ... Journal of Clinical Oncology 36 (5_suppl), 104-104, 2018 | 3 | 2018 |
| Role for immune checkpoint blockade in BRCA2-mutant prostate cancer. A Panda, MN Stein, G Riedlinger, G Bhanot, S Ganesan Journal of Clinical Oncology 37 (8_suppl), 59-59, 2019 | 2 | 2019 |
| Abstract PR05: Exceptional Response to PD-1 antibody treatment in a POLE-mutant endometrial cancer JM Mehnert, A Panda, H Zhong, KM Hirshfield, S Damare, K Stiles, ... Molecular Cancer Therapeutics 14 (12_Supplement_2), PR05-PR05, 2015 | 2 | 2015 |
| Mutation burden as a biomarker of response to immune checkpoint therapy in nine solid cancers. S Ganesan, G Bhanot, JM Mehnert, AW Silk, JS Ross, D Pavlick, SM Ali, ... Journal of Clinical Oncology 35 (7_suppl), 35-35, 2017 | 1 | 2017 |
